Real-world demographic and clinical profiles of patients with treatment-resistant depression initiated on esketamine nasal spray.
International journal of psychiatry in clinical practice June 1, 2024 Ludovic Samalin, Lila Mekaoui, Pierre De Maricourt et al. 3 citations
ESKALE is a French, multicentre, observational study of adults with treatment-resistant depression (TRD) treated with esketamine. This interim analysis describes baseline demographic and clinical characteristic evolution in patients included and treated from early access program to post-marketing launch. Data were collected from medical records and included patient characteristics, disease...